Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival

Urological Research

Volumn 24, Issue 5, 1996, Pages 257-264

  Stattin, P ^a   Damber, J E ^a   Karlberg, L ^b   Nordgren, H ^c   Bergh, A ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bcl 2; Castration; Immunohistochemistry; Prognosis; Prostate cancer; Prostatic intraepithelial neoplasia

Indexed keywords

PROTEIN BCL 2;

ARTICLE; CANCER GRADING; CASTRATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SURVIVAL;

AGED; ANDROGENS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROGNOSIS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE;

EID: 0029826151     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00304774     Document Type: Article

References (36)

1. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT (1995) Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1:473
2. Brawer MK (1992) Prostatic intraepithelial neoplasia: a premalignant lesion. Hum Pathol 23:242
3. Bronner MP, Culin C, Reed JC, Furth EE (1995) The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 146:20
4. Cambell MJ, Machin D (1993) Medical Statistics. Wiley, Chichester
5. Castle VP, Heidelberger KP, Bromberg J, Ou XG, Dole M, Nunez G (1993) Expression of the apoptosis-suppressing protein bcl-2 in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 143:1543
6. Chiarodo A (ed) (1991) Prostate cancer working group: National Cancer Institute round table on prostate cancer: future research directions. Cancer Res 51:2498
7. Colombel M, Symmans F, Gil S, Otoole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R (1993) Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390
8. Craig RW (1995) The bcl-2 gene family. Semin Cancer Biol 6:35
9. Ferguson J, Zincke H, Ellison E, Bergstrahl E, Bostwick DG (1994) Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 44:91
10. Compel A, Sabourin JC, Martin A, Yaneva H, Audouin J, Decroix Y, Poitout P (1994) Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 144:1195
11. Grönberg H, Bergh A, Damber J-E, Jonnson H, Lenner P, Ångström T (1994) Prostate cancer in northern Sweden. Incidence, survival and mortality in relation to tumour grade. Acta Oncol 33:359
12. Hockenberry D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334
13. Hockenberry DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ (1991) Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961
14. Joensuu H, Pylkkanen L, Toikkanen S (1994) Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145:1191
15. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius V-M, Niskanen E, Nordling S, Reed JC (1995) Reduced expression of proapoptotic gene box is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471
16. Lauwers GY, Scott GV, Hendricks J (1994) Immunohistochemical evidence of aberrant bcl-2 protein expression in gastric epithelial dysplasia. Cancer 73:2900
17. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL (1994) bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69:135
18. Lu-Yao GL, Greenberg ER (1994) Changes in prostate cancer incidence and treatment in USA. Lancet 343:251
19. McDonnell TJ, Nunez G, Platt FM, Hockenberry D, London L, McKearn JP, Korsmeyer SJ (1990) Deregulated Bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D expressing B-cell population. Mol Cell Biol 10:1901
20. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940
21. McNeal JE, Bostwick DG (1986) Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 17:64
22. Mostofi FK, Sesterhenn IA, Sobin LH (1980) International histological classification of prostate tumours. In: Mostofi FK (ed) International histological classification of prostate tumours. WHO, Geneva
23. Norusis MJ (1993) SPSS for Windows, SPSS Inc, Chicago
24. Pilotti S, Collini P, Rilke F, Cattoretti G, Delbo R, Pierotti MA (1994) bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 172:337
25. Raffo AJ, Perlman H, Chen M-W, Day ML, Streitman JS, Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438
26. Reed JC (1995) Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol/Oncol Clin North Am 9:451
27. Rinker-Schaeffer CW, Isaacs WB, Isaacs JT (1993) Molecular and cellular markers for metastatic prostate cancer. Cancer Metastasis Rev 12:3
28. Sabourin JC, Martin A, Baruch J, Truc JB, Gompel A, Poitout P (1994) bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 59:1
29. Shi SR, Key ME, Kalra KL (1991) Antigen retrieval in formalin-fixed paraffin embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741
30. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U (1994) The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients, J Natl Cancer Inst 86:499
31. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B (1995) bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55:237
32. Tron VA, Krajewski S, Klein-Parker H, Li G, Ho VC, Reed JC (1995) Immunohistochemical analysis of bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 146:643
33. UICC (Union Internationale Contre le Cancer) (1978) TNM classification of malignant tumours, 2 edn. Springer, Berlin Heidelberg New York
34. Vaux D, Cory S, Adams J (1988) Bcl-2 gene promotes haematopoetic cell survival and co-operates with c-myc to immortalize B cells. Nature 335:440
35. Viale G, Roncalilli M, Grimelius L, Graziani D, Wilander E, Johansson H, Bergholm U, Coggi G (1995) Prognostic value of Bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum Pathol 26:945
36. Westin P, Stattin P, Damber J-E, Bergh A (1995) Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 146:1368